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Abstract
DYSREGULATION OF MICRORNAS IN BLOOD AS BIOMARKERS FOR
DIAGNOSING PROSTATE CANCER

By Rhonda Daniel, MS
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science in Biochemistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2015

Major Director: Zendra E. Zehner, PhD. Professor, Department of Biochemistry &
Molecular Biology

Prostate cancer is the most common noncutaneous cancer among men, yet current
diagnostic methods are insufficient and more reliable diagnostic markers need to be
developed. The answer that can bridge this gap and enable more efficient diagnoses may
lie in microRNAs. These small, single stranded RNA molecules impact protein expression
at the translational level and regulate important cellular pathways. Dysregulation of these
small RNA molecules can have tumorigenic effects on cells and lead to many types of
cancers.
Currently the Prostate-Stimulating Antigen (PSA) is used as a diagnostic marker
for prostate cancer. However, many factors can elevate PSA levels such as infections and
certain medications, consequently leading to false positive diagnoses and unnecessary

xii	
  
	
  

concern and over treatment with dire outcomes for the patient. Even worse, are the
chances of false negative diagnoses, which result in prostate cancer not being diagnosed
until its later stages. Therefore, although the use of the PSA level has had its uses in the
clinic, it has failed to sufficiently bridge the gap or to distinguish indolent from aggressive
disease.
It has long been suggested in the literature that microRNAs are drastically altered
throughout the course of cancer progression. Here, RNA sequencing was used to identify
changes in miR expression profiles diagnostic for prostate cancer patients compared to
non-patient controls. The RNA sequencing results were also used to identify
normalization miRs to be used as endogenous controls. Confirmatory qRT-PCR was then
used to corroborate these results for the top seven dysregulated miRs found from the RNA
sequencing data. Data analysis of the Area Under the Curve (AUC) of the Receiver
Operating Curves (ROC) of the selected miRs exhibited a better correlation with prostate
cancer (AUC Range= 0.819- 0.950) than PSA (AUC of PSA=0.667). In summary, a panel
of seven miRs are proposed, many of which have prostate specific targets, which would
represent a significant improvement over current testing methods.
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Chapter ONE:
Introduction

	
  

I. The Prostate and Prostate Cancer (PCa)

Anatomy of the Prostate:
The prostate is an exocrine gland, and more accurately a muscle, associated with
the male reproductive system. Located below the bladder and in front of the rectum, this
gland is the size of a walnut1. The prostate surrounds the urethra, which allows it to secret
an alkaline fluid that nourishes and protects sperm from the acidity of the vagina. This
fluid comprises of about 30% of seminal fluid and contains many enzymes, such as the
prostate- specific antigen (PSA), and hormone like substances such as spermine2. It also
contains growth factors, lipids, zinc, potassium, citric acid, fructose, prostaglandins, etc.
that enhance sperm survival in the harsh environment of the vagina3.
This small gland is composed of three different cell types. The first type is the
gland cell, which produces the alkaline fluid that is secreted during ejaculation. The
second cell type is the muscle cell. During ejaculation, the sphincter muscles of the
prostate gland, as well as the bladder, close the urethra to prevent backwash of semen into
the bladder. The prostate also contains smooth muscle cells to help to expel semen during
ejaculation. The final type of cells is the fibrous cell, which provides support for the
prostate gland4.
The prostate gland is also divided into three zones, a classification technique used
mainly in pathology. The central zone is the innermost zone, which surrounds the
ejaculatory duct. About 2.5% of prostate cancers arise from this area, but tend to be more
aggressive and invasive. The transition zone surrounds the urethra and grows continuously
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throughout the lifetime of men. Because this zone is constantly growing, benign prostatic
hypertrophy (BPH) usually occurs in this zone and accounts for 10-20% of prostatic
cancers. Finally, the peripheral zone, the outermost zone of the prostate, surrounds the
distal urethra and can be felt by a physician during a digital rectal exam (DRE). This zone
composes 70% of the prostate gland and about 70% of prostate adenocarcinomas arise
from this zone5.
The prostate can also be divided into several lobes- anterior, median, lateral, and
posterior. The anterior lobe is the portion of the gland lying in front of the urethra. This
part does not contain glandular tissue and is composed exclusively of fibromuscular
tissue. For this reason, the anterior lobe rarely forms adenomas. The median lobe is
situated between the ejaculatory ducts and the urethra. Contrary to the anterior lob, the
median lobe consists of mainly glandular tissue and therefore is a common site of
adenomas. On each side of the urethra lay the lateral lobes (right and left lobes), which
form the main mass of the prostate gland. Since these lobes contain glandular tissue they
are at risk of developing adenomas at an older age. Finally the posterior lobe is located
closer to the rectum and can actually be palpated during a digital rectal exam (DRE)6.
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Diagnosis of Prostate Cancer:
The prostate specific antigen (PSA) is a prostate specific protein secreted by the
epithelial cells of the prostate gland7. This antigen is actually a protease enzyme and is a
member of the tissue kallikrein family, some of which are also prostate specific8,9. In fact,
recently, another one of its family members, human glandular kallikrein (hK2) was
discovered to be useful in detecting prostate cancer as well9. PSA is a major component of
semen where its main function is to cleave semenogelins in the seminal coagulum, which
liquefies semen to allow sperm to swim freely8. It is instrumental in dissolving the
cervical mucus and allowing for the entry of sperm into the uterus.
PSA and other kallikreins can be tissue or plasma kallikreins, which cleave peptide
bonds. There are 15 known tissue kallikreins all located in the same gene cluster on the
long arm of chromosome 19. Interestingly, a study conducted in 2003 showed that there
were sections on chromosome 19 that contained regions of tumor aggressiveness in
prostate cancer10,11. This suggests that the alleles present in this area dictate the
aggressiveness of disease, specifically prostate cancer.
About 30% of PSA in seminal plasma is the intact proteolytically active enzyme
and 5% is complexed with a protein C inhibitor. However, the majority (70%- 90%) of
PSA enter the peripheral blood complexed with a protease inhibitor, which catalytically
inactivates it. PSA can also circulate in the blood in its free form (10%-30%)8. The ratio
of free to total PSA (PSA index) has been found to be lower in patients with pCa, which
aids in differentiating between normal and pCa8. To date total PSA levels of less than 4
ng/uL in blood are considered normal while higher levels have been associated with
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prostate cancer12. However, the literature has shown that this is not always true. In one
study, 18,882 men had their PSA levels measured and of those 2,959 were found to have
PSA levels that are considered within the normal range. Among those men, prostate
cancer was diagnosed in 449 individuals, 67 of which had a Gleason score of 7 or higher.
This study showed how unreliable the use of PSA level as a diagnostic tool was in
prostate cancer13. Furthermore, even high PSA levels may not indicate prostate cancer. In
fact, studies have shown that 75% of men with elevated PSA levels do not have prostate
cancer14.
Since this method of diagnosis is clearly unreliable, the only way to make a
definitive diagnosis is by a prostate biopsy. This requires a sample of body tissue to be
removed from the prostate and examined under a microscope by a pathologist to
determine if abnormal cells are present. Only then can a conclusive diagnosis be made15.
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Grading Prostate Cancer:
After diagnosis of prostate cancer, a grading score, called a Gleason score, is given
based on the morphology of the cells seen by the pathologist. Gleason scores range from 2
to 10 and suggest the prognosis of the prostate cancer and how likely that tumor will
spread. The lower the Gleason score the more similar the cancer tissue is to the normal
prostate cells. As the score increases, the cancer cells become more distinguished from
their normal counterparts and increase the likelihood of the tumor metastasizing. A score
of 2 to 4 indicates that the cancer cells share similar characteristics to the normal cells of
the prostate and are associated with a good prognosis. A score of 5 to 7 denotes
intermediate risk with cancer tissue becoming more distinguished from normal tissue.
Finally, a score of 8 to 10 suggests little to no similarities between the cancer and normal
tissue and tend to be more aggressive in their nature16.
A detailed look at the prostate biopsy can break this score down further into two
parts. For example, a Gleason score of 8 with a break down of 3+5 indicates that the most
common tumor grade pattern seen by the pathologist was 3 while the second most
common was 5. This individual would have a better prognosis than an individual with a
Gleason score of 8 but with a break down of 5+3 because the most abundant grade pattern
was a 5 indicating that the majority of abnormal cells were morphologically more
different than the normal cells16.
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II. MicroRNA Biogenesis and Role in Disease

MicroRNA Biogenesis:
Small RNAs are an extremely important part of gene regulation. Their role in
suppression of unwanted genetic materials and transcripts is monumental to the proper
function of the body. Small RNAs are small in length (20-30 nts) and are associated with
Argonaute family proteins (AGO family proteins). They fall into three classifications
microRNAs, siRNA, and PIWI- interacting RNA (piRNA), the most dominating of which
are microRNAs17. MicroRNAs (miRs) are small non-coding RNA molecules, between 1822 nucleotides, that have been evolutionarily conserved. These miRs function at the
translational level through silencing mechanisms to regulate gene expression. The first
miR was discovered in the 1990s but it was not until the 2000s that they became
recognized as a class of biological regulators18.
More than half of known miRs are located within introns of protein coding or
noncoding transcription units. However, 10% are encoded by exons of long nonproteincoding transcripts. Biogenesis of microRNAs begins in the nucleus and continues in the
cytoplasm of cells. Transcription is carried out by RNA polymerase II, the same enzyme
that transcribes messenger RNA (mRNA) from DNA, to produce a pri-miRNA transcript
that is about 70 base pairs long. The pre- miRNA has a characteristic stem and loop
structure and can encode for more than one miR precursor. Drosha, a class II ribonuclease
III enzyme located in the nucleus, cleaves this precursor further so that it can be
transported by Exportin-5 to the cytoplasm. Pasha, an RNA recognition protein thought to

20	
  
	
  

aid in template recognition, assists Drosha. A second ribonuclease III enzyme, DICER,
cleaves the precursor once more to produce the mature form of the microRNA with the
help of another RNA recognition protein, TRBP. The mature miR then associates with the
RNA- induced silencing complex, RISC, which allows it to carry out its gene silencing
functions18.
The first 2-8 nucleotides of the miRNA, termed the seed region, determine which
mRNA is targeted19. The seed region must be complementary to the 3’ untranslated region
(3’ UTR) of the mRNA in order for silencing to occur. However, there have been
examples of miRs binding to the 5’ UTR region of the mRNA. It is also worth noting that
there are examples of miR targets where the seed region is not completely
complementary. Similarly, a complementary sequence between the microRNA and
mRNA does not always mean that it is a target. Many mRNAs are predicted to be miR
targets, but validation is required experimentally before such a conclusion can be reached.
Therefore, miRNAs can have as many as 100 predicted targets20.
MiR gene silencing mechanisms depend on how complementary the miR sequence
is to its target mRNA. If the miR sequence is completely complementary to its mRNA
target, degradation occurs. However, if the sequences do not completely match,
suppression of mRNA translation ensues by acting as a block that prevents the ribosome
from translating the mRNA into a protein20.
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Circulating microRNAs:
MicroRNAs have been found to be secreted from the cell for signaling in a
paracrine, autocrine or endocrine manner. These miRs have been found to be extremely
stable and have excited researchers as possible diagnostic biomarkers for disease.
Circulating miRs can be stored in microvesicles, exosomes, in protein complexes bound to
Ago-2 or NPM1, or in HDL particles bound to Apo21-26.
The purpose of secreted microRNAs depends on their mode of transportation. For
example, miRs secreted in vesicles appear to be secreted as a means of communication
since they do not represent the miR profile within the cells26,27. Interestingly, precursors of
many miRs are also found in these compartments28.
Since their discovery many research groups have analyzed the microRNA
composition of blood for various disease studies. Schultz et al, studied whole blood for
the identification of microRNAs that could be used as biomarkers for the detection of
pancreatic cancer. By confirmatory qRT-PCR, they found 38 microRNAs dysregulated in
whole blood including hsa-miR-150, hsa-miR-636, hsa-miR-145, hsa-miR-223, hsa-miR26b, hsa-miR-34a, hsa-miR-122, hsa-miR-126, and hsa-miR-885. They were able to
identify 2 diagnostic microRNA panels that could distinguish to a certain degree between
patients with pancreatic cancer from healthy controls29.
Another study compared microRNA levels between plasma and serum by
measuring 4 microRNAs: hsa-miR-15b, hsa-miR-16, hsa-miR-19b, and hsa-miR-24.
Interestingly, they found that there was a strong correlation in the microRNA content of
the two types of 30. Therefore both of these means would be sufficient in disease study.
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A study conducted by Andreas Keller et al, used RNA sequencing of whole blood
samples collected with PAXgene Blood tubes to study microRNA profiles in lung cancer
patients. However, samples were pooled together prior to sequencing, therefore,
preventing individual sample analysis. As a result none of these studies used RNA
sequencing to analyze miR dysregulation across different individual samples.
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MicroRNAs in Disease:
Aberrant expression of microRNAs has been associated with various diseases.
Since they play an important role in gene silencing, over expression or under expression
can lead to dysregulation of certain pathways. This is especially true in cancer where
abnormal cell growth and angiogenesis are critical for the tumorigenesis to occur. The loss
of microRNAs that suppress the translation of oncogenes, termed tumor suppressors, has
been shown in many cancers. These miRs are primarily responsible for apoptotic
pathways and cell cycle checkpoints31. Our lab previously identified miR-125b as a tumor
suppressor lost in the M12 prostate cell line which is highly tumorigenic and metastatic,
compared to the poorly tumorigenic and not metastatic parental P69 prostate cell line. By
restoring miR-125b, the migratory and invasive capability of the M12 subline was
significantly reduced32. Conversely, some miRs target tumor suppressor genes and may
become upregulated in cancer. These miRs, known as oncomiRs, allow for abnormal cell
growth and angiogenesis by inhibiting apoptotic pathways and hindering cell cycle
checkpoints. Similarly, in the M12 subline we have documented an up regulation of miR22, which targets the cellular brake PTEN, thereby contributing to enhanced tumor
growth32,33. miR-27a has also been labeled an oncomiR in the literature by targeting
prohibitin which results in a decrease in the translation of its mRNA and promotes an
increase in prostate cancer cell growth34.
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III. MicroRNAs as Diagnostic Markers for Prostate Cancer (Project Aims)

Aim 1. To identify diagnostic microRNAs in prostate cancer patients using RNA
sequencing. Hypothesis: Dysregulation of microRNAs leads to cancer. Therefore,
microRNAs will be upregulated or downregulated throughout the progression of prostate
cancer. RNA sequencing of microRNA extracted from whole blood will allow for the
identification of all miRs present in the miR expression profile of patients and controls as
well as provide insight as to which miRs may play a critical role in the progression of this
disease. Furthermore, it will provide an idea of how miRs are acting (whether they are
being upregulated or downregulated) as the disease progresses.

Aim 2. To identify a panel of miRs in blood to serve as normalizers for qRT-PCR.
Hypothesis: MiRs with constant expression across all the samples can serve as
endogenous controls, which can help to identify dysregulation of miRs that could be
diagnostic for prostate cancer.
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Aim 3. Use confirmatory qRT- PCR to substantiate RNA sequencing results as well
as determine changes in microRNA expression profiles as prostate cancer progresses.
Hypothesis: with all the advancements being made in the science field, qRT-PCR remains
the most effective and sensitive method in determining miR presence. Thus, qRT- PCR of
the same RNA samples used for RNA sequencing will be used to confirm miR
dysregulation. For the most part, miRs chosen for validation will be based on those shown
to be dysregulated via RNA sequencing analysis and supported by the literature where
possible.

	
  

Chapter TWO:
Methods and Materials

	
  

This chapter is a comprehensive discussion about the techniques used to isolate
and analyze RNA from samples and controls. A total of 12 controls and 28 patient
samples were extracted and analyzed using the methods discussed below. Various
limitations and advantages for each technique are discussed as well.

I. Extraction
Protocol:
Plasma and whole blood samples from patients and normal individuals were
obtained from the Nelson Urology Clinic and the Hunter Holmes McGuire VA Medical
Center in compliance with their respective IRBs. Plasma samples were collected in
purple- capped EDTA tubes to prevent cell lysis and whole blood samples were collected
in PAXgene blood collection tubes (PreAnalytiX, a Qiagen/ BD company). PAXgene
tubes contain a reagent that lyses blood cells and immediately stabilizes intracellular RNA
to prevent degradation. For this reason, the tubes were left at room temperature for a
minimum of two hours after collection. Plasma was spun down at 3,000 rpm as soon as
the sample was collected to prevent cell lysis and the supernatant was then placed in 1.5
mL microtubes in 500 µL aliquots to be stored at -80C.
A corresponding extraction kit, PAXgene Blood microRNA kit, was used to
extract microRNA from the PAXgene collection tubes according to the manufacturer’s
instructions (PreAnalytiX, a Qiagen/ BD company). This kit allowed for preferential
extraction of RNA within the length parameters of microRNAs using a silica membrane.
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The isolated RNA was eluted in 80 µL of elution buffer and stored at -80C.
Supernatant aliquots were processed using the miReasy Plasma/ Serum extraction
kit according to manufacturer’s instructions (Qiagen). Aliquots were complied onto a
single RNeasy® MinElute® Spin Column and eluted in 25 µL of elution buffer. All RNA
samples were stored at -80C.

Principle:
RNA is susceptible to rapid degradation by nucleases present in blood within
hours of blood extraction. Furthermore, gene regulation, such as induction and repression,
can lead to changes in transcript levels, which can change the overall RNA profile.
PAXgene collection tubes combat this issue by the inclusion of a liquid reagent that
stabilizes intracellular RNA to prevent changes in the gene expression profile24.
The miRNEasy Serum/ Plasma kit was designed for the purification of small RNA
such as miRNA, from small volumes of serum. It uses a silica- membrane- based
purification method to isolate and purify total RNA. The QIAzol Lysis thiocynate
facilitates the lysis of cells, denatures proteins and RNases. Addition of chloroform allows
nucleic acid, both RNA and DNA, to be efficiently partitioning in the aqueous solution
and denatured proteins to be discarded in the interphase. The addition of ethanol at 0.5X
volume of aqueous volume precipitates RNA, which is then preferentially bound to the
spin column so that other contaminants can be washed away.

4	
  
	
  

Limitations:
Several problems arose during the course of experimentation. Initial PAXgene
blood tubes collect whole blood in a stabilizing solution, but the subsequent miR
extraction kit appears to enhance for microRNAs. Although this increase in the yield of
miRs results in sufficient RNA for sequencing analysis, this technique would not be ideal
to use for studies interested only in analyzing circulating microRNAs. However, we could
not obtain sufficient RNA for next generation sequencing from the usual small amounts of
patient plasma necessitating starting with whole blood. Nonetheless, theoretically, any
cellular miR contamination that is seen in the patient profiles will be comparable to the
patient profile IF it is not due to disease. As a result, it was felt that for the purposes of
this study, whole blood would suffice because regardless of the source of the miR (cellular
or plasma), if it turns out to be diagnostic for prostate cancer, it’s useful. Furthermore, at
this time it is not clear which miR particle- exosomes, microvesicles, apoptotic bodies, or
bound to proteins such as Arg-, or HDL- would be most diagnostic for prostate cancer
detection. Thus at this stage, our approach is not limited to any one particle, which could
jeopardize results, rather we are including all particles in our analysis. Future experiments,
will be needed to determine if any one of these different types of microRNA containing
particles is superior to the other in predicting disease.
Nonetheless, to begin an investigation into the possibility, a few plasma samples
were also collected in order to compare the circulating miR profile of patients and controls
with their corresponding whole blood profile. This allowed for a comprehensive look at
what miRs are being excreted and what miRs are due to cellular contamination.
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Furthermore, enhancement for some miRs could potentially skew the miR profile
in favor of overly expressed miRs while wiping out the documentation of less abundant
miRs. This possibility will be further discussed in the next chapter, Chapter 3, as this is
also a concern for bias in analyzing RNA sequencing results.
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II. Bioanalyzer:

Protocol:
Samples were stored in 2 µL aliquots and heat denatured for 2 minutes at 70 °C.
Bioanalyzer analysis was run according to manufacturers protocol using the pico chip and
smallRNA chip assay (Agilent).

Principle:
The bioanalyzer allows for the quantification and qualification of extracted
microRNA. The small RNA chip contains 11 sample wells, 3 gel wells, a conditioning
solution well, and an external standard (ladder). The cells are interconnected to form an
integrated electrical circuit. The bioanalyzer has 16 pin electrodes that fit in the 16 well
chip, each with its own power supply, which allows for each sample to be run
independently. A voltage gradient is created in each well causing charged molecules such
as RNA to migrate, much like gel electrophoresis. The constant mass-to-charge ratio and
sieving polymer matrix allows the molecules to be separated based on their respective
size. The ladder includes six fragments ranging from 25 nucleotides to 150 nucleotides at
150 ng/ µL. By comparison to the ladder, miR quantification and size can be determined.
When the fluorescent dye intercalates within the RNA the detector senses the RNA and
determines the size and quality.
The advantage of running the pico chip lays in the fact that it shows small RNA as
well as ribosomal RNA. Identification of the ribosomal contamination helps determine
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how much of the sample is actually needed for RNA sequencing which requires 100 ng/
µL of total RNA (Figure 2-1A). However, the small RNA chip is able to separate small
RNA more effectively to better determine a microRNA concentration within the 10 nt- 40
nt region (Figure 2-1B). Interestingly, we decided to determine the comparability and
reproducibility between the two chips and found that the concentrations were remarkably
close. To calculate the small RNA concentration in a sample run on the pico chip, the
ribosomal contamination was subtracted from the total RNA concentration. The resulting
number was amazingly close to the small RNA concentration determined by the small
RNA chip.
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A.

B.

Figure 2-1 Representative Patient Comparison of Bioanalyzer Results from Pico Chip and Small RNA
Chip: Whole blood (2 uL) was analyzed using the pico chip and the small RNA chip. This is a
representative patient bioanalyzer comparing between the two chips. (A): Pico Chip: The 18S and 28S
show the ribosomal concentration present in the sample. The percentage of contamination is reported here as
30.3%. Therefore to determine the small RNA concentration the concentration of ribosomal contamination
was subtracted from total RNA concentration (4853.9 pg/ uL). This number is remarkably close to the small
RNA concentration that is seen in the small RNA chip. (B): Small RNA Chip: Small RNA concentration as
well as microRNA concentration are reported here.
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Limitations:
The bioanalyzer, while useful at determining the approximate concentration of
microRNAs, does not allow for exact quantification. It analyzes a range between 10-40 nt
as the microRNA range although it is known that miRs fall within the 18-20 nt range. As a
result the concentration reflected in the bioanalyzer results is an overestimate of the
microRNA concentration in a given sample. Furthermore, the small RNA chip does not
allow for the determination of ribosomal contamination. Although the pico chip was
originally used and the ribosomal contamination was determined to be minimal, it was
impossible to estimate ribosomal contamination for the samples seen on the small RNA
chip alone. Prohibitive costs did not allow all samples to be analyzed on both chips and
since a determination of miR concentration was the more important value to determine, all
samples were analyzed on the small RNA chip.
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III. RNA Sequencing:

Protocol:
100 ng/ µL of each sample was sent to the Core for sequencing using the Illumina
TruSeq Small RNA Library Prep platform according to manufacturers protocol.

Principle:
RNA 3’ adapters are ligated onto each sample followed by the 5’ adapter to bring
the small RNA size to ≅ 70 base pairs. For pair end sequencing, two indices are added to
the sample as well to allow for the forward and reverse sequencing of the template strand.
The RNA sample is then run on a gel to separate RNA based on size. At this point, the
desired size (microRNA with ligated adaptor sequences and index sequences) falls in the
145 base pair region. Reverse transcription polymerase chain reaction (RT-PCR) is the
carried out to synthesize a single stranded cDNA. The cDNA is then PCR amplified using
a common primer and a primer containing 1 of 24 index sequences, which allows for the
separation of the indexes and the RNA ligation reaction. “This design allows for the
indexes to be read using a second read and significantly reduces bias compared to designs
that include the index within the first read.” The resulting cDNA is then gel purified and
extracted. Once these isolated cDNAs are applied to the flow cell, there is cluster
amplification.
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Limitations:
Although RNA sequencing is a useful method because it allows scientists to
determine what miRs are being expressed and the pattern of expression, it remains limited
in some aspects. Analysis between batches is difficult due to “batch effects.” These effects
are inherent in any batch due to technical sources of variation that can be added to the
samples during handling. Therefore comparison between two batches requires statistical
analysis to correct for these differences. Furthermore, the various techniques that can be
used in RNA sequencing such as paired end analysis or shotgun (single end) sequencing
prevents the pooling of two batches for dual analysis. Therefore, it is important to be
mindful of these limitations during the analysis of different RNA sequencing batches in
order to prevent the addition of biases.
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IV. qRT- PCR

Protocol:
Three ng of each RNA sample was converted into 20 µL cDNA using the
qScriptTM cDNA synthesis kit according to manufacturers protocol (Quanta). The cDNA
was then diluted 1:2 and 2 µL were used for each PCR reaction run in triplicate. PCR was
conducted on several miRs (Quanta Primers) discussed in the subsequent chapters using
the qScriptTM One- Step SYBR Green qRT-PCR kit according to manufacturers protocol
(Quanta).

Principle:
The SYBR Green mix used contains all the components needed for the polymerase
reaction including dNTPs, magnesium chloride, AccuStart Taq DNA polymerase,
stabilizers, and SYBR Green I dye. When added to the cDNA sample and heated,
denaturation yields a single strand as well as liberation of the DNA polymerase from its
stabilizers (95 °C for 2 minutes). Upon cooling to the optimal annealing temperature (60
°C for 30 seconds), the primer can then anneal to the template strand and elongation
(extension) can take place (70 °C for 30 seconds). This cycle is repeated for 40 cycles. At
the end of each extension cycle the amount of SYBR Green bound to the double strand
DNA product emits a fluorescent signal. The amount of this signal is quantitated, and the
signal intensity increases each cycle as the PCR product accumulates. Once this signal
reaches a preset threshold value the cycle number is noted. This threshold value is set to
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be within the optimal amplification range of the cDNA sample. The lower the Cycle
threshold (CT) value the more abundant the primer, and hence the miR, is in the samples.
Vice versa, the higher the CT value, the less expressed the miR is in the sample.
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Chapter 3
Next Generation Sequencing (NGS) Analysis

	
  

Introduction:
Next Generation Sequencing (NGS) is a relatively new method for the development of
miR profiles. High- throughput NGS platforms provide researchers with the ability to analyze
whole miR expression profiles with low amounts of microRNA input and quick output of
results. This is a far cry from the First GS methods such as Sanger sequencing, which require
cloning of one miR, amplification of that single miR and finally sequencing one base at a time.
In contrast, the Illumina high- throughput platform and its sister platforms allow millions of
reads to be sequenced at the same time.
A major advantage of RNA sequencing is its ability to distinguish miRs with even
single nucleotide differences, such as the Let family. Since these differences fall outside the
seed region of the miRNA, the targets of members of this family can differ vastly and the
clinical implications of dysregulation change33. As a result, the fact that NGS can distinguish
between these family members allows researchers to determine which miRs are important in
disease. Furthermore, NGS can discriminate between isomiRs, which are a result of posttranscriptional additions to the 3’ end, and less frequently the 5’ end, of mature miRs. Another
major advantage of NGS is identification of the whole miR profile of a sample. All miRs that
are present in the sample will be represented in the sequencing profile. As a result, researchers
can determine which miRs are worth validating with qRT-PCR.
RNA sequencing does, however, have its disadvantages. Despite being much more
expensive than other methods, it still does not provide the sensitivity of qRT-PCR. For this
reason validation of the miR expression profile is required. Moreover, since there are a limited
number of oligonucleotides to bind to the adaptor sequences within a sample lane, microRNAs
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that are abundant may be biasedly expressed in the sequencing profile than less abundant miRs.
Therefore, when analyzing the sequencing results, it is important to keep these limitations in
mind or the project runs the risk of excluding important miRs. Finally, significant adaptor
trimming, genome alignment, and statistical analysis are required after resulting sequencing
reads are obtained.
As discussed in the Methods and Materials section, the Illumina platform was used to
analyze the miR profiles of controls and patients. Two different sequencing methods were
available, including shotgun sequencing and pair-end sequencing. Shotgun sequencing is a
quick method that allows for rapid output of results. Large fragments are sheered into smaller
fragments about 30 to 350 nt long, which make it easier to sequence. The fragments are then
reassembled into their original order based on overlapping sequences, which ultimately yields
the complete sequence. However, this method runs the risk of producing unknown sequences at
certain positions and is not very reliable when analyzing longer sequences. For the purposes of
microRNA studies, literature suggests that while this is much less of a problem due to the small
length of microRNAs, small sequencing errors were still seen in the results35.
Pair- end sequencing, however, is more rigorous due to the sequencing of both ends of
the fragment as discussed in the Methods and Materials section. Therefore, high- quality reads
are generated which increases the likelihood of proper alignment to the reference genome.
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Analysis:
For this study, three separate RNA sequencing batches were sent to the Nucleic Acids
Research Facility at Virginia Commonwealth University. In total, 12 control samples and 28
patient samples (Table 3-1) ranging from elevated PSA to G9, with one sample from a patient
with metastatic disease (*as noted) were studied (Table 3-2). When age, race/ethnicity, or PSA
level was provided, they are reported here. Furthermore, although the majority of the patient
samples collected were G7-G8, an almost equal number of lower grade prostate cancer with
good prognosis (G2-G6) and higher grade prostate cancer with poor prognosis (G7-G9) were
obtained with 16 samples and 12 samples in each group respectively. Paired end sequencing
using the Illumina platform was conducted as stated in the methods and materials section.
Analysis of the RNA sequencing results was then preformed using multiple programs including
Partek, RStudio, and edgeR.
Partek® Flow® is an online software program developed by Partek incorporated that
analyzes RNA sequencing data. A pre-alignment QA/QC was run on the unaligned reads prior
to analysis to determine the quality of the NGS raw data (Figures 3- 1A and 3- 1B). The
Average base quality score per position (Figure 3-1A) shows that the quality of bases at
positions 16 to 45 have the highest quality scores. The Average base quality score per read
(Figure 3- 1B) indicates that the Phred quality score is not uniform among the reads. Therefore,
additional trimming of the adaptors and bases was necessary to increase the quality of the raw
data.
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Flow® was then used to trim the adaptor sequences
(AGATCGGAAGAGCACACGTCT) ligated to the 3’ and 5’ ends of the templates as used by
the Illumina sequencing TruSeq Small RNA sample preparation kits. The default settings were
used except for determining the parameters for match times and the min read length. In some
instances the adaptor sequence may anneal more than once so changing the match times from 1
(default) to 3 allowed the sequence to be cleaved up to 3 times from a single read. The min read
length was changed from 25 to 16 since microRNAs are 18-22 nucleotides long.
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Table 3- 1: Sample Log List

Sample
Name
03132014a
03132014b
03132014c
03132014d
04292014!
05132014!
05242014!
06062014!
09182014!
10212014
12172014a
12172014b
12192014
02162015!
02162015!
GG
40 P.Y.J
36 K.A.B
18 E.H.D
9 Q.M.A
72 W.J.C
100 C.T.L
56 J.D.J
85 D.T
33 H.E.W
20 A.O.E
31 E.M.R
62 M.A.V
51 D.L.D
6 W.H.C
83 R.L.J
16 E.W.J
82 J.R.D
8 R.M.S
89 B.R.W
03242015 K.B
V.J
03262015
04062015 W.L
04242015 M.A
04282014 S.S

Control
Gleason
or Patient
Score
PATIENT
7
PATIENT
7
PATIENT
7
PATIENT
9
PATIENT
PATIENT
PATIENT
9
PATIENT
CONTROL
CONTROL
PATIENT
7
PATIENT
CONTROL
CONTROL
CONTROL
CONTROL
PATIENT
7
PATIENT
7
PATIENT
6
PATIENT
6
PATIENT
8
PATIENT
7
PATIENT
7
PATIENT
7
PATIENT
6
PATIENT
6
PATIENT
6
CONTROL
PATIENT
7
PATIENT
6
PATIENT
6
PATIENT
8
PATIENT
7
PATIENT
6
PATIENT
7
CONTROL
CONTROL
CONTROL
CONTROL
-

PSA
Age Race/ Ethnicity
Level
Elevated
Elevated
92
Caucasian
22
Caucasian
Elevated
51
Caucasian
24
Caucasian
24
Caucasian
Caucasian
3.42
66
Caucasian
10.73
55
Caucasian
6.8
68 African American
8.82
55
Asian/ Hawaiian
4.77
63
Caucasian
7.78
61 African American
4.57
68
Caucasian
6.1
65
Caucasian
3.2
63
Caucasian
4.15
64 African American
12.47
67
Caucasian
39 African American
6.06
64
Caucasian
11
58 African American
4.21
66
Caucasian
7.99
76
Caucasian
8.36
62 African American
4.4
73 African American
3.5
66
Caucasian
46
43
Caucasian
91
Caucasian
59
Caucasian
55
Asian/ Hawaiian
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Bioanalyzer
(ng/ µ L)
4.77405
4.2512
6.25885
2.34317
2.6643
4.81057
7.48465
2.41735
1.01513
1.57365
3.531
6.3641
4.74255
11.1381
5.7136
13.07285
2.49433
3.79373
278.41495
0.82855
2.6045
1.5708
5.0533
1.9734
1.7158
0.1449
0.183
6.2787
13.801
5.8854
12.8379
2.5383
7.79565
10.2831
10.7295
3.0372
2.1404
15.8662
2.0354
2.453

Table 3- 2: Number of Samples for each Prostate Grade

Prostate Cancer Grade

Number of Samples

Elevated PSA

4

G3- G4

0

G5- G6

8

G7-G8

14

G9 + Mets

2
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A.

B.

Figure 3- 1: Pre- alignment Analysis of QA/QC- Raw Data: (A): Pre- alignment QA/QC of Average base
quality score per position. This graph shows the average quality score of each base. It is obvious that the bases at
the beginning (Positions 1-16) and the bases at the end (46-139) have very low quality scores indicating a need to
trim these bases off. (B): Pre- alignment QA/QC Average base quality score per read. This graph shows the
quality score per read. This indicates that about 5% of the reads have a phred score of 26 suggesting that trimming
is required to ensure that all the reads have quality scores of 38 or greater.
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Another pre-alignment QA/QC report was generated to determine if the adaptor
sequences were properly cleaved (Figures 3- 2A and 3- 2B). The two graphs indicate an
increase in the quality of the bases and the overall reads but further trimming was required.
Trimming of bases on both ends of all the reads permits removal of partial sequences that may
have been inserted into the template during cDNA library prep and amplification. Removal of
these “junk” sequences allows for increased quality (Phred quality scores) of the reads and
trims away bad quality bases that could affect alignment. A final pre-alignment QA/QC report
was generated (Figures 3- 3A and 3- 3B) to show that all the bases had similar quality scores
and that the average base quality for the majority of the reads was now at a Phred score of 39,
where a Phred score of 30 is considered exceptional. This score indicates that there is a 1 in
every 7,943 chance of an incorrect base call and that the base call accuracy is 99.99%. This prealignment data was convincing that the data was of high quality and that the analysis could
continue.
Next the raw data had to be aligned to the human genome to determine the chromosome
number as well as the start and stop positions of each read compared to the reference genome.
The Bowtie aligner was utilized using the updated Genome Reference Consortium (GRCh38),
with three parameters altered. Seed mismatch limit was altered from the flexible 2-mismatch
value to a more stringent value of 1-mismatch, which ensured that any read that aligned to the
genome was in fact a match.
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A.

B.

Figure 3- 2: Pre- alignment QA/QC- Adaptors Trimmed: (A): Pre- alignment QA/QC of Average base quality
score per position after Trimming of Adaptor Sequences. This graph shows the average quality score of each base.
It is obvious that the bases at the beginning (Positions 1-13) and the bases at the end (46-139) have very low
quality scores indicating a need to trim these bases off. (B): Pre- alignment QA/QC Average base quality score per
read after Trimming of Adaptor Sequences. This graph shows the quality score per read. This indicates that more
than 100% of the reads have a Phred score higher than 31 with the majority of reads having a Phred score of 38.
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A.

B.

Figure 3- 3: Pre- alignment QA/QC- Bases Trimmed: (A): Pre- alignment QA/QC of Average base quality
score per position after Trimming of Bases. This graph shows the average quality score of each base. The quality
of all the bases was above 36 indicating that the trimming was successful. (B): Pre- alignment QA/QC Average
base quality score per read after Trimming of Bases. This graph shows the quality score per read. This indicates
that more than 100% of the reads have a Phred score higher than 35 with the majority of reads having a Phred
score of 39.
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Furthermore, seed length was changed from 28 to 16 because, again, the length of microRNAs
is smaller than the default settings. Finally, the alignments reported per read was increased
from 1 to 3, which increased the number of valid alignments reported. Bowtie aligner was
selected because it is the most suitable for short, high quality reads with high similarity and
highly unique alignments. A post- alignment QA/QC report was generated (Figures 3- 4A, 34B, 3- 4C, 3- 4D) and the quality of the samples remained the same after alignment. The
alignment per read (Figure 3- 4C) shows that the majority of the reads lined up 3 times as the
parameter was set and that the rest lined up more than twice. This allows for confidence in the
reported miR profile. Furthermore, the alignment percent (Figure 3- 4D) was extremely high
with an average of 90% lining up to the miR base, which indicated that the samples did not
contain notable contamination.
The data was then quantified to the transcriptome using Partek E/M, which reports the
number of reads for each miR that was aligned to the transcriptome. This provides the user with
a preliminary idea of what the miR profile looks like.
Differential expression analysis was then conducted using edgeR in order to normalize
the raw sequencing reads. This step allows for the minimization of technical bias and ensures
that the differences in miR expression are truly due to biological difference. As in any study,
various steps introduce bias to the results. In the case of RNA sequencing the main concern is
gene length, sequencing depth, and RNA composition35.
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A.

B.

C.

D.

Figure 3- 4: Post- alignment QA/QC: (A): Post- alignment QA/QC of Average base quality score per position
after Trimming of Bases. The quality of all the bases was above 36 indicating that the trimming was successful.
(B): Post- alignment QA/QC Average base quality score per read after Trimming of Bases. This indicates that
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more than 100% of the reads have a Phred score higher than 37 with the majority of reads having a Phred score of
39. (C): Average Alignments per Read. Majority of samples aligned between 2.5 to 3 times. (D): Alignment
Breakdown. All samples had a high alignment percentage.
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The most commonly utilized normalization methods for RNA sequencing is Reads Per
Kilobase Per Million Mapped Reads (RPKM) and total counts. The RPKM method was first
proposed by Mortazavi et al. (2008) and operates on the notion that the number of reads of a
certain gene tends to be proportional to the length of the gene36. On the other hand, the total
counts method divides the raw reads of each transcript in a sample by the corresponding total
number of reads in the sample which adjusts for the library size37.
However, these normalization methods have their limitations. Both of these methods
only take the length of the gene and its expression level into account while excluding the effect
of RNA composition, which also has a great impact on downstream differential expression
analysis. In any given sample, highly expressed genes may cause an under representation of
lower expressed genes leading to a false positive detection of dysregulated genes. Furthermore,
microRNAs all fall within the 18- 22 nt length and therefore the use of gene length is not
effective to normalize miRNA deep sequencing data. Thus, a new normalization method that
places emphasis on RNA composition rather than length was necessary.
For this reason, Trimmed Mean of M-values (TMM) proposed by Robinson et al.
(2012), which normalizes by considering RNA composition, was utilized instead36. This
method relies on the hypothesis that most genes are in fact not differentially express. The edgeR
software, the statistical component of R, operates using the TMM normalization method and
was used for all differential expression analysis38.
This generated 550 miRs with their associated p-values and false detection rates or false
discovery rates (FDR) (Table 3-3). A significant p value was any value at or below the standard
value of 0.05. A value equal to or less than that standard cutoff suggests that the null hypothesis
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(meaning there is no real dysregulation in the miR profile between controls and patients) can be
rejected BUT does not mean that the dyregulation observed is actually due to biological
variation. The most significant aspect of an extremely low p value is that it controls for Type 1
errors, which are the incorrect rejection of a true null hypotheses or false positives. The FDR
further helps with minimizing Type 1 errors by controlling the proportion of rejected null
hypotheses that were incorrect. Since there were 550 miRs expressed at appreciable values, a
FDR value of 0.2 was selected meaning that ≈110 out of 550 miRs would be expected to
produce false positives. With the parameters set as stringently as possible, this produced 26
miRs to investigate further for dyregulation (Table 3-3).
The resulting data was used to determine which miRs to pursue for the normalization
and dysregulation studies. An analysis of these results will be discussed in the following
chapters.
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Table 3- 3: Sample Log List Generated from RNA Sequencing Results

MicroRNA
hsa-miR-5582-3p
hsa-miR-32-5p
hsa-miR-500b-3p
hsa-miR-329-3p
hsa-miR-487b-3p
hsa-miR-454-3p
hsa-miR-204-5p
hsa-miR-20a-5p
hsa-miR-127-3p
hsa-miR-543
hsa-miR-5001-3p
hsa-miR-181a-3p
hsa-miR-144-3p
hsa-miR-660-3p
hsa-miR-374a-5p
hsa-miR-128-3p
hsa-miR-654-5p
hsa-miR-17-5p
hsa-miR-4676-3p
hsa-miR-20b-5p
hsa-miR-18b-5p
hsa-miR-134-5p
hsa-let-7f-2-3p
hsa-miR-642a-5p
hsa-miR-942-5p
hsa-miR-4433a-3p

P Value
2.36E-06
1.23E-05
0.000572225
0.001109288
0.001200988
0.00150438
0.001930515
0.002972257
0.003157203
0.00347709
0.004038855
0.004057331
0.004134586
0.004346684
0.004572518
0.005373932
0.006803665
0.006906872
0.007747569
0.007983965
0.008218656
0.008416145
0.00944494
0.009733771
0.010041576
0.010133679
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FDR
0.001298179
0.00337548
0.10471709
0.131868458
0.131868458
0.137650814
0.151407567
0.167354157
0.167354157
0.167354157
0.167354157
0.167354157
0.167354157
0.167354157
0.167354157
0.184393041
0.206237737
0.206237737
0.206237737
0.206237737
0.206237737
0.206237737
0.206237737
0.206237737
0.206237737
0.206237737

Chapter 4
Normalization

	
  

Introduction:
After analysis of the RNA sequencing results, it became evident that a normalization
method needed to be developed to validate miR dysregulation detected in qRT-PCR assays as
due to biological variation or just technical error. Variation within a data set can be due to
“true” biological variation, i.e. caused by changes within the organism, which experimenters
wish to document or due to technical variations that are caused by experimental errors. During
the course of any study, many systemic and random errors can accumulate, which add to the
variation in the results. Systemic errors affect all the samples in a data set in the same way and
cause similar deviations from the real value causing predictable and proportional differences.
Random errors, however, as the name suggests, are much more difficult to eliminate because
they instill unpredictable fluctuations in the results effecting the precision. Such errors can arise
from the experimenter or instabilities in the apparatus.
For this reason, normalization techniques are imperative to eliminate the bias that arises
from these errors and to ensure that the observed variation is in fact due to “true” biological
variation. The best way to normalize is to use an endogenous control. Such controls should be
present within the organism as part of the miR profile and are stably expressed across both
patients and controls.
One of the major disconcerting aspects of many microRNA studies is the lack of a
reliable normalizer. Many studies still rely on the use of members of the RNU family, also
known as snoRNAs, which are small nucleolar RNAs. However, these non- coding RNAs have
been found to be unreliable endogenous controls when dealing with whole blood, serum, and
other body fluids because they are located within cells and are not actively secreted into the
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body fluids unless left behind as degradation products from cellular debris. Moreover, one study
analyzed breast cancer paraffin embedded samples and found that snoRNAs were actually
downregulated39. Another limiting factor is that normalization candidates can vary between
different body fluids and diseases, making it even more difficult to find a universal
normalization technique. Thus normalization standards had to first be determined before
confirmatory miR dysregulation studies could be pursued.
For the purposes of this study, the RNA sequencing data was used to determine which
miRs were stably expressed across all the samples. Once normalizers were identified, several
factors were taken into consideration to determine which miRs should be analyzed further using
qRT-PCR. The first factor was the standard deviation between the normalized reads. A small
standard deviation was desired to ensure that the normalized miRs exhibited constant
expression amongst all the samples. Second, the abundance was taken into consideration. Very
low abundance miRs would yield high CT reflecting lower concentrations in the sample,
therefore proving to be unreliable normalized candidates. On the other hand, miRs that were
expressed too highly could wipe out dysregulation differences and instill bias in the results.
Finally, the coefficient variance was calculated (standard deviation divided by the mean) to
standardize the variability between sample populations.
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Results:
After analysis of the RNA sequencing results, several candidates showed convincing
potential as normalizers including hsa-miR-874-3p, hsa-miR-15b-3p, hsa-miR-6783-3p, hsamiR-4511, hsa-miR-6842-3p, hsa-miR-139-3p, hsa-miR-1468-5p, hsa-miR-92a-1-5p, hsa-miR202-5p, hsa-miR-197-3p, hsa-miR-671-3p, hsa-miR-933, hsa-miR-1248, hsa-miR-628-5p, hsamiR-146a-5p, hsa-miR-92b-5p, hsa-miR-5193, hsa-miR-342-5p, hsa-miR-659-5p, hsa-miR23a-3p, hsa-miR-423-3p, hsa-miR-3909, hsa-miR-296-5p, hsa-miR-340-3p, hsa-miR-769-5p,
hsa-miR-1538. A box plot of the RNA sequencing data for each of these miRs in control and
patient samples is shown in Figure 4-1A through Figure 4-1Z.
A review of the literature was also conducted to determine if there was any overlap
between these potential miRs and the RNA sequencing results. Although some of these studies
investigated miRs in different body fluids, it was important include a literature review to ensure
that the best candidates were chosen for further investigation. Several miRs were suggested to
be suitable normalization miRs are as follows; hsa-miR-130b in prostate tissue40, hsa-miR-191
in the urine of prostate cancer patients and controls41, hsa-miR-103 in T-cell acute
lymphoblastic leukemia (T-ALL) samples42, and hsa-miR-93 in normal and cancerous human
solid tissues43. Box plots of their analysis in the RNA sequencing data are shown in Figure 42A through Figure 4-2D.
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U.
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W.

X.

Y.

Z.

Figure 4- 1: Normalized Reads of Possible
Normalization Candidates from RNA
Sequencing Results: Normalization Candidates:
MiRs that were selected for exploratory qRT-PCR
have a red border. MiRs that were then selected by
NormFinder to be effective normalization standards
contain two asterisks next to the microRNA name.
MiRs were selected based on small standard
deviations between patients and controls, their
abundance, and finally a small coefficient variance.
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A.

B.

C.

D.

Figure 4- 2: Normalized Reads of Normalization Candidates from Literature Review: Candidates suggested by
the literature as normalization candidates. (A): MiR-130b was not selected as a normalization candidate due to the
difference in the means between patient and control samples. (B): MiR- 191 was found to be extremely abundant in the
samples and was not selected for normalization for fear that it would wipe out dyregulation. (C) and (D): These miRs
were found to be extremely dysregulated displayed extremely low p values associated with them. As a result they were
not selected as normalization candidates.
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As can be seen in the graphs in Figures 4-1 and 4-2, some of the candidates were too
abundantly expressed, were expressed at very low levels, or were too variable among the
sample population. Moreover two of the miRs suggested in the literature (Figures 4-2C and 42D) showed dyregulation and even presented extremely low p values as shown in their
respective graphs. Therefore, of the 30 miRs suggested via RNA sequencing results, 8 were
selected for exploratory qRT- PCR (Figure 4-1- figures with one asterisk or two asterisks
were selected for exploratory PCR).
The results of the CT values generated for each selected miR in qRT- PCR data are
shown in Figure 4-3. Interestingly, most of the normalization candidates produced extremely
small standard deviations between samples within the same group or different groups (Table 41). Small standard deviations are desired for normalization candidates. NormFinder analyzes
intra- and intergroup variations to determine which candidates are best suited. Although miR197 has a higher standard deviation compared to two other miRs, its standard deviation is
consistent between controls and patients. These standard deviations were smaller than those
observed in the RNA sequencing results, although all these selected miRs all proved to be
promising.
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Figure 4- 3: CT Values from qRTPCR of Normalization Candidates: CT
Values of Normalization Candidates:
Normalization candidates that were
identified by NormFinder to have the
lowest stability values have a red border.
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Figure 4- 4: CT Values from qRT-PCR of Normalization Candidates: Graph depicting the collective CT
Values of all the normalization candidates: As can be seen miR-1538, miR- 1468-3p, and miR-146a-5p all
exhibited small standard deviations as well as similar CT values. MiR-1248 and miR-197 also displayed small
standard deviation although lower CT values.

Table 4- 1: Standard Deviation of Normalization miRs

MiR
MiR 197-3p
MiR 15b-3p
MiR 296-5p
MiR 23a-3p
MiR 146a- 5p
MiR 1248
MiR 1468-3p
MiR 1538

Std
between Controls
2.896500338
2.544328016
2.467039537
3.776250299
1.344533392
2.168850477
2.438152474
1.273392193

Std
between Patients
2.644989917
2.370826007
1.840413884
2.837212083
2.078563461
2.497720751
2.070897156
1.544603799
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Std between
Controls and Patients
2.708628336
2.377684418
2.128742552
3.249625057
1.713997946
2.288752129
2.186690811
1.382686823

NormFinder:
After exploratory PCR was conducted on the 8 selected candidates, the statistical
program NormFinder was then utilized to determine which combinations of these miRs would
provide the best normalization standards. NormFinder was chosen as opposed to other available
programs that are available because the authors use an algorithm that is NOT susceptible to
preferring miRs that are co-regulated. It was felt that such a preference could further bias our
results. This program uses a linear model that takes into account intragroup and intergroup
variation. This means that observed fluctuations that are seen between individuals in the same
group are compared to fluctuations seen between patients and controls.
Based on this analysis a stability value is allocated to each miR. A small stability value
is associated with the best normalization candidate because it indicates small intra- and
intergroup variability (Figure 4-5). The bolded numbers that are in blue represent the four best
values and the miRs that were selected as the normalization panel for this study. The program
also provides the user with the best combination of two miRs and the composite stability value
of those two miRs (Table 4-2). A lower stability value for a combination of two miRs ensures
that smaller variations are seen between the two groups. The program does not allow for the
analysis of any computation of miRs greater than two. Thus, it was not possible to calculate a
stability value for all four miRs together, but since the stability value of a single miR (miR-146a)
went from 0.009 to 0.008 with the addition of miR-1538, it is projected that a combined stability
of all four would be extremely favorable. Therefore, for the purposes of this study, a geometric
mean of the four best miRs determine by NormFinder were determined to be the most reliable.
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MiR 296-5p
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Figure 4- 5: Stability Value Generated by NormFinder: Stability Values and their corresponding miRs: A list
of the stability values of the eight microRNAs explored via qRT-PCR. The ones that are bolded and are in blue
represent the four best values and the miRs that were selected as the normalization panel for this study.
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Table 4- 2: Top miRs Selected by NormFinder

Best gene

MiR 146a- 5p

Stability value

0.009

Best combination of two genes

MiR 146a- 5p and MiR 1538

Stability value for best combination of two genes
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0.008

Chapter 5
Dysregulated miRs Results

	
  

Analysis:
The RNA sequencing data of blood revealed that there were potentially 26 dysregulated
miRs that yielded acceptable p- values and FDR values (<0.05 and 0.2 respectively) (Table 3-1
and Figure 5-1A through Figure 5-1Z). Analysis of the box plots showed that the best
candidates to pursue for further validation were the first nine miRs with the lowest p- values and
lowest FDRs (Figure 5-1A- Figure 5-1I). However, the primers for hsa-miR-5582-3p and hsamiR-500b-3p could not be obtained by Quanta in time for the purposes of this study and will
therefore be analyzed at a later time (Figure 5-1A and Figure 5-1C).
Consequently, that left four upregulated miRs and three downregulated miRs. Hsa-miR127-3p, hsa-miR-204-5p, hsa-miR-329-3p and hsa-miR-487b-3p where shown to be upregulated
in the RNA seq data and hsa-miR-20a-5p, hsa-miR-32-5p and hsa-miR-454-3p was observed to
be downregulated.

Results:
qRT-PCR assays confirmed these findings (Figure 5-2A through Figure 5-2N). The box plots as
well as their corresponding dot plots are shown along with their associated p-values. The plots were
produced by subtracting the raw CT value of the miR being studied by the geometric mean of the four
selected normalizers. Both plots were shown because the box plot effectively displays the standard
deviation of the samples within each group, whereas if outliers are present they can be more clearly
noted in the dot plot.
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Figure 5-1: Normalized Reads of
Dysregulated miRs: Normalization Reads of
Dysregulated Candidates: Dysregulated
candidates were selected based on p values,
FDR values and limited overlap between
patients and controls. Asterisks represent the pvalue. Three asterisks are smaller p-values
compared to the one asterisk, which has a pvalue of less than 0.05 but higher than 0.01.
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Figure 5-2: Box plots and Dot plots of Normalized CT Values of Dysregulated MiRs: Box plots and
Dot plots of Dysregulated MiRs: each of these plots displays the p-value associated with the miR.
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It is easy to spot two of the outliers in the control group in the dot plots for hsamiR-127-3p, hsa-miR-204-5p , hsa-miR-329-3p, and hsa-miR-487b-3p (Figures 5-1B, 51D, 5-1F, 5-1H). Interestingly, these two samples were consistently the two younger
controls (the 24 year-olds) that were included in this study. It is possible that these
oncomiRs are being gradually upregulated with age and thus the two youngest samples
display the lowest expression levels. Furthermore, these young control samples also
showed the greatest expression of tumor suppressor miRs compared to their older
counterparts (Figures 5-1J, 5-1L, and 5-1N).
It is also interesting to note that the oldest control (92 years old) and the family
history control sample both exhibited intermediate miR profiles more similar to patient
samples than controls for some of these miRs. These two samples regularly displayed
lower amounts than the rest of the control samples in the dot plots (Figures 5-1J, 5-1L,
and 5-1N). Likewise, this same pattern was observed for two oncomiRs (Figures 5-1F
and 5-1H). The 92 year-old control and the family history control displayed higher
concentrations of these oncomiRs in similar fashion to the patient samples.
The Receiver Operating Curve (ROC) for each of the dysregulated miRs was then
generated. This curve provides a graphical plot to illustrate the performance of two groups
as the discrimination threshold is varied. The curve is created by plotting the true positive
rate (sensitivity) against the true negative rate (1- specificity) at varying thresholds to
determine the curve. The sensitivity identifies the proportion of positives that are correctly
identified as positives (i.e. a patient sample identified as prostate cancer positive) whereas
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the specificity identifies the proportion of negatives that are correctly identified as such
(i.e. a control samples identified as prostate cancer negative).
The ROC curve is extremely important because it shows the tradeoff between
sensitivity and specificity. As sensitivity increases, the specificity decreases- the ROC
curve demonstrates just how great this tradeoff actually is. The Area Under the Curve
(AUC) was then calculated to determine how accurate each miR was at discriminating
between patients and controls. The greater the area, the more accurate the miR is at
discriminating between patients and controls. The AUC of the ROC curve for PSA, the
standard measurement for prostate cancer diagnosis, is 0.678. For the seven selected
miRs, all the AUCs of their respective ROC curves were significantly higher than that of
PSA (Figure 5-3A through 5-3G).
These promising AUCs lead us to believe that constructing a panel of these 7 miRs
could prove to be more diagnostic than PS A alone. By using a panel of relevant miRs, a
diagnosis of prostate cancer would be best substantiated by the dysregulation of several
miRs not based on just one as with PSA.
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Figure	
  5-‐3:	
  ROC	
  Curves	
  of	
  Selected	
  m iRs:	
  ROC	
  curves	
  of	
  
the	
  7	
  selected	
  miRs	
  with	
  their	
  associated	
  AUC.	
  As	
  can	
  be	
  
seen,	
  all	
  the	
  miRs	
  have	
  an	
  AUC	
  that	
  is	
  higher	
  than	
  that	
  of	
  
PSA	
  (AUC=	
  0.667)	
  indicating	
  that	
  they	
  may	
  be	
  better	
  
diagnostic	
  markers.	
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Chapter 6
Targets of Dysregulated miRs

	
  

Analysis of RNA sequencing results and validation by qRT PCR identified 7 miRs
to be of value in diagnosing prostate cancer. All of these miRs generated ROC curves with
AUC values considerably better than PSA (AUC=0.667), the current gold standard for
diagnosing prostate cancer. A review of these miRs, their chromosomal location, possible
targets and a projected role in cancer with particular emphasis on prostate cancer when
data is available are discussed below.
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I. Upregulated miRs in Blood:

hsa-miR-127-3p:
MiR 127-3p is located on the long arm of chromosome 14. It is situated near a
cluster of microRNAs including hsa-mir-431, hsa-mir-433, hsa-mir-432, and hsa-mir-136.
This miR is embedded in a CpG island that is susceptible to epigenetic silencing44.
MiR 127-3p has been found to be lost in glioblastoma proliferation (GBM). GBM
is a multistep process during which the expression levels of many genes controlling cell
proliferation, cell death, and genetic stability are altered. This study used RNA sequencing
on brain tissue and found that miR-127-3p was significantly downregulated in GBM
patients. They also found that this microRNA targets SKI, an oncoprotein hence activating
TGF- beta45.
This miR is also downregulated in breast cancer tissue and has been shown to
target BCL6. Decreases in miR-127-3p showed marked increases in the oncoprotein
BCL6. This protein plays an important role in cell proliferation by suppressing
transcription of the anti-apoptotic BCL-XL gene or the adhesion molecule VCAM46,47.
Therefore, its aberrant expression in cancerous cells promotes tumorigenesis. Chen et al
(2013) also showed that over expression of miR-127 or depletion of BCL6 inhibited breast
cancer proliferation thereby supporting the tumor suppressor ability of miR-127 on the
oncoprotein BCL648.
As can be seen in previous results from blood shown above in Figures 5-1I, 5-2A,
5-2B, this miR was found to be upregulated in blood from prostate cancer patient samples.
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hsa-miR-329-3p:
MiR-329-3p is a nonintronic miR located on the short arm of chromosome 14. It is
part of an extensive miR cluster containing over 40 miRs total. One of the miRs in this
study, miR-487b-3p, is also part of this extensive cluster and will be discussed more
extensively in the next section. Another miR in this cluster, miR-543, located less than
200,000 bases away, was found to be significantly dysregulated with an appreciable p
value and FDR value (Figure 5-1J) and will be studied at a later time.
In a study conducted by Yang et al (2014), miR-329-3p was found to be
downregulated in neuroblastoma metastatic tumor tissue compared to the primary tumor.
When SH-SY5Y cells, a human neuroblastoma cell line, were transfected with miR-329,
the growth and motility of the cells was significantly suppressed and prevented colony
formation. They also conducted studies to determine potential targets of this miR. One
promising target was KDM1A, which has been shown to be a tumorigenic protein49.
Another research group studying recurrent prostate cancer found that KDM1A was
significantly upregulated in the LnCaP androgen dependent prostatic cell lines. When this
protein was depleted using siRNA, VEGF-A expression was also decreased which in turn
blocked androgen induced VEGF-A, PSA, and Tmprss2 expression50.
Interestingly, a study on metastatic prostate cancer cells found that 10 miRs in this
cluster, including miR 329 and miR 487b were significantly downregulated. This study
also found an inverse correlation between increased Gleason scores and metastases versus
decreases in expression. In addition, these miRs were found to play an important role in
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regulating proliferation, apoptosis, migration and invasion in metastatic prostate cancer
cells.
Once again, the inverse is seen in blood from prostate cancer patients with a
significant upregulation in miR 329-3p as opposed to what is detected in various tissue
and prostate cell lines.
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hsa-miR-487b-3p:
MiR 487 is located almost 15 kb way from miR-329 on the same microRNA
cluster on chromosome 14. This miR, like miR-329, has been found to be downregulated
in prostate cancer cell lines51. Another study by Gattolliat et al, also showed that miR487b-3p was downregulated by 5.75 fold in neuroblastomas tissue samples52.
An interesting predicted target for miR-487b-3p was ALDH1A3, aldehyde
dehydrogenase 1A3, an enzyme known to be upregulated in the LnCaP prostate cancer
cell lines. When LnCaP cells are exposed to the androgen dihydrotestosterone (DHT), this
protein increased 4-fold. This protein has also been implicated in breast cancer metastases
and is therefore notably an oncomiRic protein53.
Once again, the literature shows an inverse relationship to what the RNA
sequencing and confirmatory qRT-PCR data on whole blood samples has shown in this
study.
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hsa-miR-204-5p:
MiR-204-5p is located on chromosome 9 in the sixth intron of its host gene
TRPM3, transient receptor potential cation channel subfamily M member 3. TRPM3 is
important for cellular calcium signaling and maintaining homeostasis. Interestingly, miR204-5p is located in a cancer- associated genomic region in the long arm of chromosome 9
and has been shown to be extremely downregulated in many tumor types including breast,
kidney and prostate54.
Wang et al (2010) had previously shown that reduction in the expression of miR204- 5p led to reduce expression of claudins 10,16, and 19, which decreased
transepithelial resistance by 80% and reduced cell membrane voltage and conductance.
They also showed that absence of 204-5p also led to decrease in Kir7.1 proteins, which
connect TGF-BR2 and maintain potassium homeostasis. Therefore this miR plays a
crucial role in maintaining epithelial barrier function and cell physiology54. Another study
showed that 204-5p suppressed the growth, migration and invasion of endometrial
carcinomas by binding TrkB mRNA and interfering with JAK2 and STAT3
phosphorylation55.
Similarly to miR-127-3p, miR-204-5p was also upregulated in prostate cancer
patient blood samples, opposite to what has been shown in the literature when dealing
with tissue samples.
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II. Downregulated miRs in Blood:

hsa-miR-20a-5p:
MiR-20a-5p, located on chromosome 13, is part of the 17/92 cluster, which has
been implicated in age related diseases. It has been found that this cluster is vital to
normal development and plays an important role in cell cycle, proliferation, apoptosis, and
other processes. One of the most studied targets of miR-20a is the E2F family, particularly
E2F2 and E2F3, which play a role in cell cycle regulation. This miR also targets several
cyclin dependent kinases, including p21 and p57, which halt the cell cycle in case of
aberrant division. Finally, another notable target is FasI, which promotes cell death.
Interestingly, the major targets of this miR promote tumorigenesis and angiogenesis by
preventing cell cycle checkpoints56.
One study using tumor tissues from prostate cancer patients found that MiR-20a
was significantly higher in dedifferentiated CaP cells. The over expression of this MiR has
also been shown in the PC3 prostate cancer cell lines using PCR and microarray studies
on tissue57. Once again, this study found that this miR binds E2F2 and E2F3 mRNAs in
the 3’ UTR and play a crucial role in the cell cycle58.
As with the rest of the of miRs, our results from the RNA sequencing and
confirmatory qRT-PCR data tell the opposite story for this miR. It has been found to be
downregulated in blood samples from patients.
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hsa-miR-32-5p:
Finally, miR-32-5p, located on chromosome 9, has been found to be an androgenregulated miR that targets BTG2. This miR is overexpressed in castration- resistant
prostate cancer (CRPC). An increase in 32-5p expression levels was associated with
reduced apoptosis in tumor samples by targeting the 3’ UTR of BTG2 and preventing
apoptosis59.
Furthermore, this miR was discovered to be regulated by DHT and showed that
putative Androgen Receptor- binding sites (ARBSs) upstream without other genes nearby.
This miR was also found to be downregulated in patient blood samples.
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hsa-miR-454-3p:
MiR- 454-3p is located on chromosome 17 in the first intronic region of SKA2, its
host gene. SKA2, also known as Spindle and Kinetochore Associated Complex Subunit 2,
is essential for proper chromosome segregation. During the cell cycle both, SKA2 and
miR 454-3p have been shown to be upregulated.
MiR 454-3p has been shown to target the B cell Translocation Gene 1 (BTG1) that
has long been recognized as a tumor suppressor gene. BTG1 plays an important role in
cell cycle progression and is involved in stress responses. This anti-proliferative gene is
expressed at its highest concentration during the G0/G1 phases of the cell cycle and then
downregulated when the cell progresses through G1 phase60.
A study showed that in renal carcinoma cells, an increase in 454-3p displayed a
marked decrease in BTG1 via a direct interaction with the 3’ UTR of BTG1 mRNA.
Furthermore, their cell cycle analysis showed that when 454-3p was overexpressed, it
shifted the cell cycle arrest from G2/M into S phase60.
Interestingly, a second study also found miR-454-3p was overexpressed in chronic
myeloid leukemia by targeting TGFBR2 (Transforming Growth Factor, beta Receptor II),
a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. This
receptor/ligand complex phosphorylates proteins that enter the nucleus and regulates the
transcription of genes related to cell proliferation. An increase of miR-454-3p in myeloid
leukemia led to a decrease in this receptor61.
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As with the rest of the miRs, this miR showed the inverse expression in blood as to
what is shown in the literature. RNA sequencing and confirmatory qRT-PCR data showed
that this miR was downregulated in patient blood samples.
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III. Comparison of miR expression in Blood to the TGCA Database:

Remarkably, the literature showed an opposite result to what our RNA sequencing
data and confirmatory qRT-PCR displayed. In an effort to better characterize the role of
these 7 miRs in prostate cancer, a comparison was made to data from the Cancer Genome
Atlas (TCGA) database. Here, RNA sequencing data preformed on 495 prostate cancer
tumor samples as well as tumor-free margins from the same patient was deposited into a
database as overseen by the National Cancer Institute (NIH) and made freely available for
review by investigators.
Interestingly, this comparison also showed an inverse relationship between miR
expression levels detected in blood compared to actual prostate tumor tissue. For example,
miRs that were found to be upregulated in our blood samples were found to be tumor
suppressors lost in tumors in the TCGA data. The opposite was also true, miRs
downregulated in blood were found to be aberrantly overexpressed as oncomiRs in tumor
tissue.
A search of the literature found that several studies have found a similar
comparison to be true for many miRs, although not all. This raises the question of whether
oncomiRs in tumor samples were being retained within the tumor for the benefit of tumor
growth and therefore what escapes into the blood is decreased. On the other hand, tumor
suppressors that could block tumor growth were being dumped out into the blood.
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Chapter 7
Conclusions

	
  

RNA sequencing of microRNAs is a fairly new technique and none of the previous
studies in the literature analyzed individual miR profiles of patient and control samples.
All these studies pooled samples together in order to obtain sufficient material for RNA
sequencing. This method prevents an analysis of variability across individual sample
profiles and blocks any correlation to the stage of disease when Gleason scores are
available. Not only is it important to diagnose prostate cancer, but also identify
biomarkers that can serve to stage disease or separate indolent from aggressive disease
which is even more important to subsequent treatment options. Therefore, the fact that our
RNA sequencing data examined 40 samples individually without pooling, enabled us to
analyze trends those other studies were not able to evaluate. It also permitted us to
determine outliers and hypothesize why those outliers might act differently than the rest of
the group.
Furthermore, the lack of reliable normalization candidates has been crippling to
many studies. The RNA sequencing data allowed us to select miRs that were consistent
across all 40 samples and report reliable normalization miRs that can be used for the
analysis of qRT-PCR in blood. The geometric mean of miR-197-3p, miR-1538, miR1468-3p, and miR-146a-5p has shown to be remarkably consistent among all the patients
and controls, thus providing reliable miRs for normalization.
It was important to confirm RNA sequencing results with qRT-PCR.
Significantly, results from these two very different methodologies agreed well further
supporting the quality of our approach. All the miRs with low p-values and low FDR
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values in the RNA sequencing data showed extraordinary p-values with qRT-PCR and
astonishing AUCs. This was extremely encouraging because thus far investigators have
been determining which miRs to study by reviewing the literature. Thus, they are limited
to analyzing only those miRs that have already been shown to be dysregulated in disease.
However, RNA sequencing allows for the identification of all possible diagnostic
miRNAs both known and novel, expanding the spectrum of miRs that can contribute to
disease.
Here, an interesting discovery was the inverse relationship between blood miR
expression levels and tumor expression levels. Since all of our blood miRs displayed an
inverse expression level with tumor samples, we propose that it is possible that tumors are
retaining oncomiRs for the purpose of driving tumorigenesis and angiogenesis and
therefore, less of these oncomiRs are released into the blood. Conversely, tumor
suppressors block tumor growth and may need to be disposed of to enhance tumorigenesis
and ultimately metastasis, hence the increase in blood levels of these miRs. If this was the
case for only one or two miRs, perhaps not, but recurrence supports this hypothesis.
It has been shown that cancer cells secrete vesicles containing not only mature
miRs to modify their environment for future metastasis, but the entire processing
machinery (dicer, RISC with premiR) to ensure that once taken up by the target cell, the
miR is efficiently processed and actively moved into translational silencing of target
mRNAs. It is felt that if only the mature miR was delivered, it might not be as efficient in
modifying translation within the target cell. With this in mind, it is not much of a stretch
to propose a developing tumor wants to dispose of compromising miRs that could restrict
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its growth; thus, excluding tumor suppressor miRs. Concomitantly, holding onto an
oncomiR to quickly modulate the proteome is fast and efficient, faster than modifying
gene expression at the transcriptional level. Similar studies to ours for other cancers need
to be completed to determine the overall merits of this hypothesis.
Since three of the miRs on our panel belong to the same mega cluster on
chromosome 14, it would also be interesting to evaluate more of the miRs from this
cluster. After a more recent review of our data, we found several additional miRs from
this cluster with low p-values and FDR values, which need to be further evaluated. It
would be interesting to see if these miRs are also increased in patient blood samples as
opposed to the TCGA tumor samples further supporting our hypothesis. Studies have
shown that the miRs in this cluster are downregulated during tumorigenesis through
mechanisms that are unknown. If increases in these miRs are found in blood, it is possible
to hypothesize that the expression of these miRs is not being turned off at the
transcriptional level but that they are being shuttled out of the tumor cell and into the
blood as a survival and growth mechanism.
In summary, the 7 miR panel that we have developed shows that miR-127-3p,
miR-329-3p, miR-487b-3p, miR-204-5p, miR-20a-5p, miR-454-3p, and miR-32-5p
display higher diagnostic capabilities than PSA measurements. ROC curves and AUC
values are outstanding compared to the current PSA gold standard. Further studies need to
be conducted to determine a threshold level for each of these miRs that can diagnose
prostate cancer.
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The four upregulated miRs in patient blood (miR-127-3p, miR-329-3p, miR-487b3p, and miR-204-5p) that cumulatively target BCL6, KDM1A, ALDH1A3, and TrkB
which have been shown to be important regulators of prostate cancer. These proteins have
been shown to have oncogenic effects on tissue and therefore these miRs are tumor
suppressors that are lost in tumorigenesis. On the other hand, the three downregulated
miRs in patient blood (miR-20a-5p, miR-32-5p, and miR-454-3p) have been shown to
target the tumor suppressor proteins E2F2, BTG2, and BTG1 respectively. Although they
were downregulated in our patient blood samples, they have been shown to be oncomiRs
in tumor tissue.
Another value of this suggested panel is that the four upregulated miRs in blood
and 3 downregulated miRs in blood serve as internal controls for each other thereby
serving to verify the accuracy of the panel results (i.e. they don’t all go up or all go down).
Constructing a panel with only downregulated miRs is always hard to justify however by
pairing the loss of these three miRs with the increase in the other four miRs allows for
greater diagnostic confidence.
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